DUBLIN, July 15, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into agreements with Quoin Pharmaceuticals Inc.

View post: 25-year-old women’s fashion chain closes stores, no bankruptcy Terms of the deal call for Malvern, Pa.-based Endo to pay C$77 for each Paladin share, a premium of 20% to the target’s $63.91 ...

MALVERN, Pa., Feb. 26, 2014 /PRNewswire/ -- Endo Health Solutions Inc. (NASDAQ: ENDP) ("Endo") today announced that, at the shareholder meeting held today, proposals related to Endo's proposed ...

MONTREAL, Jan. 22, 2024 /PRNewswire/ -- Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI ® (cenobamate tablets) is now available in Canada. XCOPRI is ...

MALVERN, Pa. (AP) -- Endo Health will spend about $1.5 billion to buy the Canadian specialty drug maker Paladin Labs, and both will then be folded into a newly-formed Irish holding company. Endo also ...

Endo Health Solutions ($ENDP) needs a shot in the arm, now that its lead drug Lidoderm faces generic competition. And Endo may have found just that. The has company ...

Shares of Endo International were choppy in intraday trade Friday after a report said it has held talks to sell Paladin Labs, its specialty pharmaceutical subsidiary. The pharma company may sell it to ...

(Reuters) - Endo International Plc has discussed a sale of Paladin Labs Inc, its Montreal-based specialty pharmaceutical subsidiary, to Canadian drug maker Knight Therapeutics Inc , people familiar ...

Endo Health Solutions Inc. agreed to buy Canadian specialty-pharmaceutical company Paladin Labs Inc. for about $1.6 billion, allowing Endo to continue its transition into a specialty health-care ...